BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 31525487)

  • 1. Clinical features of neuroendocrine prostate cancer.
    Conteduca V; Oromendia C; Eng KW; Bareja R; Sigouros M; Molina A; Faltas BM; Sboner A; Mosquera JM; Elemento O; Nanus DM; Tagawa ST; Ballman KV; Beltran H
    Eur J Cancer; 2019 Nov; 121():7-18. PubMed ID: 31525487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological characteristics and survival outcomes in neuroendocrine prostate cancer: A population-based study.
    Zhu J; Liang X; Wu D; Chen S; Yang B; Mao W; Shen D
    Medicine (Baltimore); 2021 Apr; 100(15):e25237. PubMed ID: 33847621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer.
    Wang J; Xu W; Mierxiati A; Huang Y; Wei Y; Lin G; Dai B; Freedland SJ; Qin X; Zhu Y; Ye DW
    Prostate; 2019 Sep; 79(13):1563-1571. PubMed ID: 31376193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroendocrine Carcinoma as an Independent Prognostic Factor for Patients With Prostate Cancer: A Population-Based Study.
    Yao J; Liu Y; Liang X; Shao J; Zhang Y; Yang J; Zheng M
    Front Endocrinol (Lausanne); 2021; 12():778758. PubMed ID: 34956090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contemporary Incidence and Cancer Control Outcomes of Primary Neuroendocrine Prostate Cancer: A SEER Database Analysis.
    Zaffuto E; Pompe R; Zanaty M; Bondarenko HD; Leyh-Bannurah SR; Moschini M; Dell'Oglio P; Gandaglia G; Fossati N; Stabile A; Zorn KC; Montorsi F; Briganti A; Karakiewicz PI
    Clin Genitourin Cancer; 2017 Oct; 15(5):e793-e800. PubMed ID: 28506524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment.
    Kadakia KC; Tomlins SA; Sanghvi SK; Cani AK; Omata K; Hovelson DH; Liu CJ; Cooney KA
    J Hematol Oncol; 2015 Oct; 8():109. PubMed ID: 26444865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and Biological Features of Neuroendocrine Prostate Cancer.
    Yamada Y; Beltran H
    Curr Oncol Rep; 2021 Jan; 23(2):15. PubMed ID: 33433737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of Second-Line Therapies in Patients With Metastatic de Novo and Treatment-Emergent Neuroendocrine Prostate Cancer: A Multi-Institutional Study.
    Eule CJ; Hu J; Al-Saad S; Collier K; Boland P; Lewis AR; McKay RR; Narayan V; Bosse D; Mortazavi A; Rose TL; Costello BA; Bryce AH; Lam ET
    Clin Genitourin Cancer; 2023 Aug; 21(4):483-490. PubMed ID: 37193610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment-Emergent Neuroendocrine Prostate Cancer: A Clinicopathological and Immunohistochemical Analysis of 94 Cases.
    Zhang Q; Han Y; Zhang Y; Liu D; Ming J; Huang B; Qiu X
    Front Oncol; 2020; 10():571308. PubMed ID: 33598420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of intraductal carcinoma of the prostate detected by initial histological specimen and neuroendocrine prostate cancer: A report of three cases.
    Ikeda J; Ohe C; Ohsugi H; Matsuda T; Tsuta K; Kinoshita H
    Pathol Int; 2021 Sep; 71(9):621-626. PubMed ID: 34297443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma.
    Chedgy EC; Vandekerkhove G; Herberts C; Annala M; Donoghue AJ; Sigouros M; Ritch E; Struss W; Konomura S; Liew J; Parimi S; Vergidis J; Hurtado-Coll A; Sboner A; Fazli L; Beltran H; Chi KN; Wyatt AW
    J Pathol; 2018 Oct; 246(2):244-253. PubMed ID: 30015382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Outcomes in Neuroendocrine Prostate Cancer.
    Iwamoto H; Nakagawa R; Makino T; Kadomoto S; Yaegashi H; Nohara T; Shigehara K; Izumi K; Kadono Y; Mizokami A
    Anticancer Res; 2022 Apr; 42(4):2167-2176. PubMed ID: 35347041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platinum sensitivity in metastatic prostate cancer: does histology matter?
    Humeniuk MS; Gupta RT; Healy P; McNamara M; Ramalingam S; Harrison M; George D; Zhang T; Wu Y; Armstrong AJ
    Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):92-99. PubMed ID: 29230006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative study of neuroendocrine acquisition and biomarker expression between neuroendocrine and usual prostatic carcinoma.
    Xiao GQ; Ho G; Suen C; Hurth KM
    Prostate; 2021 Jun; 81(8):469-477. PubMed ID: 33848377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and management of neuroendocrine prostate cancer.
    de Kouchkovsky I; Chan E; Schloss C; Poehlein C; Aggarwal R
    Prostate; 2024 Apr; 84(5):426-440. PubMed ID: 38173302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spatial Gene Expression Analysis Reveals Characteristic Gene Expression Patterns of De Novo Neuroendocrine Prostate Cancer Coexisting with Androgen Receptor Pathway Prostate Cancer.
    Watanabe R; Miura N; Kurata M; Kitazawa R; Kikugawa T; Saika T
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.
    Beltran H; Oromendia C; Danila DC; Montgomery B; Hoimes C; Szmulewitz RZ; Vaishampayan U; Armstrong AJ; Stein M; Pinski J; Mosquera JM; Sailer V; Bareja R; Romanel A; Gumpeni N; Sboner A; Dardenne E; Puca L; Prandi D; Rubin MA; Scher HI; Rickman DS; Demichelis F; Nanus DM; Ballman KV; Tagawa ST
    Clin Cancer Res; 2019 Jan; 25(1):43-51. PubMed ID: 30232224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy considerations in neuroendocrine prostate cancer: what next?
    Beltran H; Demichelis F
    Endocr Relat Cancer; 2021 Jul; 28(8):T67-T78. PubMed ID: 34111024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy with atezolizumab for small cell or neuroendocrine carcinoma of the prostate: A single institution experience.
    Wee CE; Costello BA; Orme JJ; Quevedo JF; Pagliaro LC
    Prostate; 2021 Sep; 81(13):938-943. PubMed ID: 34254332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer.
    Zhang C; Qian J; Wu Y; Zhu Z; Yu W; Gong Y; Li X; He Z; Zhou L
    Pathol Oncol Res; 2021; 27():1609968. PubMed ID: 34646089
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.